SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kraig Biocraft Laboratories, Inc – ‘S-1’ on 6/2/20 – ‘EXCEL’

On:  Tuesday, 6/2/20, at 4:47pm ET   ·   Accession #:  1493152-20-10402   ·   File #:  333-238883

Previous ‘S-1’:  ‘S-1/A’ on 6/2/15   ·   Next:  ‘S-1/A’ on 8/24/20   ·   Latest:  ‘S-1/A’ on 11/22/23   ·   22 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/02/20  Kraig Biocraft Laboratories, Inc  S-1                   71:7.9M                                   M2 Compliance/FA

Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Registration Statement (General Form)               HTML   1.20M 
 2: EX-14.2     Code of Ethics                                      HTML     72K 
 3: EX-23.1     Consent of Experts or Counsel                       HTML     21K 
 4: EX-99.1     Miscellaneous Exhibit                               HTML     61K 
 5: EX-99.2     Miscellaneous Exhibit                               HTML     47K 
 6: EX-99.3     Miscellaneous Exhibit                               HTML     42K 
14: R1          Document Entity Information                         HTML     34K 
48: R2          Condensed Consolidated Balance Sheets               HTML    120K 
58: R3          Condensed Consolidated Balance Sheets               HTML     49K 
                (Parenthetical)                                                  
31: R4          Condensed Consolidated Statements of Operations     HTML     89K 
15: R5          Condensed Consolidated Statement of Changes in      HTML     79K 
                Stockholders Deficit                                             
49: R6          Condensed Consolidated Statement of Changes in      HTML     25K 
                Stockholders Deficit (Parenthetical)                             
59: R7          Condensed Consolidated Statements of Cash Flows     HTML    110K 
32: R8          Summary of Significant Accounting Policies and      HTML    114K 
                Organization                                                     
13: R9          Going Concern                                       HTML     28K 
37: R10         Equipment                                           HTML     35K 
20: R11         Right to Use Assets and Lease Liability             HTML     56K 
50: R12         Accrued Interest - Related Party                    HTML     32K 
60: R13         Note Payable                                        HTML     28K 
38: R14         Stockholders' Deficit                               HTML    157K 
21: R15         Commitments and Contingencies                       HTML     81K 
51: R16         Related Party Transactions                          HTML     63K 
61: R17         Subsequent Events                                   HTML     29K 
39: R18         Summary of Significant Accounting Policies and      HTML    153K 
                Organization (Policies)                                          
19: R19         Summary of Significant Accounting Policies and      HTML     62K 
                Organization (Tables)                                            
41: R20         Equipment (Tables)                                  HTML     33K 
66: R21         Right to Use Assets and Lease Liability (Tables)    HTML     40K 
26: R22         Stockholders' Deficit (Tables)                      HTML    145K 
22: R23         Summary of Significant Accounting Policies and      HTML     49K 
                Organization (Details Narrative)                                 
42: R24         Summary of Significant Accounting Policies and      HTML     43K 
                Organization (Details Narrative) (10-K)                          
67: R25         Summary of Significant Accounting Policies and      HTML     30K 
                Organization - Schedule of Antidilutive Securities               
                of Earnings Per Share (Details)                                  
27: R26         Summary of Significant Accounting Policies and      HTML     28K 
                Organization - Schedule of Antidilutive Securities               
                of Earnings Per Share (Details) (Parenthetical)                  
23: R27         Summary of Significant Accounting Policies and      HTML     35K 
                Organization - Schedule of Deferred Tax Assets and               
                Liabilities (Details) (10-K)                                     
40: R28         Summary of Significant Accounting Policies and      HTML     24K 
                Organization - Schedule of Deferred Tax Assets and               
                Liabilities (Details) (10-K) (Parenthetical)                     
68: R29         Summary of Significant Accounting Policies and      HTML     31K 
                Organization - Schedule of Components of Deferred                
                Income Taxes (Details) (10-K)                                    
64: R30         Summary of Significant Accounting Policies and      HTML     28K 
                Organization - Schedule of Fair Value of Financial               
                Instruments (Details)                                            
54: R31         Summary of Significant Accounting Policies and      HTML     34K 
                Organization - Schedule of Concentration of Credit               
                Risk (Details) (10-K)                                            
18: R32         Going Concern (Details Narrative)                   HTML     33K 
36: R33         Going Concern (Details Narrative) (10-K)            HTML     33K 
63: R34         Equipment (Details Narrative)                       HTML     25K 
53: R35         Equipment (Details Narrative) (10-K)                HTML     25K 
17: R36         Equipment - Schedule of Property and Equipment      HTML     37K 
                (Details)                                                        
35: R37         Right to Use Assets and Lease Liability - (Details  HTML     59K 
                Narrative)                                                       
62: R38         Right to Use Assets and Lease Liability - (Details  HTML     65K 
                Narrative) (10-K)                                                
55: R39         Right to Use Assets and Lease Liability - Schedule  HTML     28K 
                of Right Use of Assets (Details)                                 
71: R40         Right to Use Assets and Lease Liability - Schedule  HTML     33K 
                of Lease Liability (Details)                                     
44: R41         Right to Use Assets and Lease Liability - Schedule  HTML     27K 
                of Lease Cost (Details)                                          
25: R42         Accrued Interest - Related Party (Details           HTML     45K 
                Narrative)                                                       
30: R43         Accrued Interest - Related Party (Details           HTML     45K 
                Narrative) (10-K)                                                
70: R44         Note Payable (Details Narrative)                    HTML     41K 
43: R45         Note Payable (Details Narrative) (10-K)             HTML     41K 
24: R46         Stockholders' Deficit (Details Narrative)           HTML    186K 
29: R47         Stockholders' Deficit (Details Narrative) (10-K)    HTML    179K 
69: R48         Stockholders' Deficit - Schedule of Option          HTML     86K 
                Assumption (Details)                                             
45: R49         Stockholders' Deficit - Schedule of Warrants        HTML     52K 
                Activity (Details)                                               
46: R50         Stockholders' Deficit - Schedule of Warrants        HTML     59K 
                Outstanding (Details)                                            
56: R51         Stockholders' Deficit - Schedule of Options         HTML     31K 
                Outstanding (Details)                                            
33: R52         Commitments and Contingencies (Details Narrative)   HTML    355K 
16: R53         Commitments and Contingencies (Details Narrative)   HTML    311K 
                (10-K)                                                           
47: R54         Related Party Transactions (Details Narrative)      HTML    272K 
57: R55         Related Party Transactions (Details Narrative)      HTML    293K 
                (10-K)                                                           
34: R56         Subsequent Events (Details Narrative) (10-K)        HTML     35K 
65: XML         IDEA XML File -- Filing Summary                      XML    128K 
28: EXCEL       IDEA Workbook of Financial Reports                  XLSX     95K 
 7: EX-101.INS  XBRL Instance -- kblb-20200331                       XML   2.05M 
 9: EX-101.CAL  XBRL Calculations -- kblb-20200331_cal               XML    133K 
10: EX-101.DEF  XBRL Definitions -- kblb-20200331_def                XML    814K 
11: EX-101.LAB  XBRL Labels -- kblb-20200331_lab                     XML    909K 
12: EX-101.PRE  XBRL Presentations -- kblb-20200331_pre              XML    959K 
 8: EX-101.SCH  XBRL Schema -- kblb-20200331                         XSD    178K 
52: ZIP         XBRL Zipped Folder -- 0001493152-20-010402-xbrl      Zip    146K 


‘EXCEL’   —   IDEA Workbook of Financial Reports


This is an IDEA Workbook.

        Download this Microsoft® Excel® .xlsx workbook


22 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/22/23  Kraig Biocraft Laboratories, Inc. S-1/A                 67:13M                                    M2 Compliance LLC/FA
 9/01/23  Kraig Biocraft Laboratories, Inc. POS AM                67:13M                                    M2 Compliance LLC/FA
 9/01/23  Kraig Biocraft Laboratories, Inc. S-1/A                 67:13M                                    M2 Compliance LLC/FA
 6/06/23  Kraig Biocraft Laboratories, Inc. S-1/A                 66:13M                                    M2 Compliance LLC/FA
 5/09/23  Kraig Biocraft Laboratories, Inc. S-1/A                  1:2.2M                                   M2 Compliance LLC/FA
 4/27/23  Kraig Biocraft Laboratories, Inc. S-1/A                  1:2.2M                                   M2 Compliance LLC/FA
 4/14/23  Kraig Biocraft Laboratories, Inc. S-1/A                 65:9.9M                                   M2 Compliance LLC/FA
 4/14/23  Kraig Biocraft Laboratories, Inc. POS AM                65:9.1M                                   M2 Compliance LLC/FA
12/01/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:14M                                    M2 Compliance LLC/FA
 5/25/22  Kraig Biocraft Laboratories, Inc. S-1/A                 64:12M                                    M2 Compliance LLC/FA
 4/14/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:10M                                    M2 Compliance LLC/FA
 3/23/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:9.7M                                   M2 Compliance LLC/FA
 2/10/22  Kraig Biocraft Laboratories, Inc. S-1                   67:13M                                    M2 Compliance LLC/FA
12/03/21  Kraig Biocraft Laboratories, Inc. S-1/A                 64:13M                                    M2 Compliance LLC/FA
 8/25/21  Kraig Biocraft Laboratories, Inc. S-1/A                 63:12M                                    M2 Compliance LLC/FA
 5/26/21  Kraig Biocraft Laboratories, Inc. S-1/A                 86:9.3M                                   M2 Compliance LLC/FA
 4/15/21  Kraig Biocraft Laboratories, Inc. S-1/A                  1:74K                                    M2 Compliance LLC/FA
 4/14/21  Kraig Biocraft Laboratories, Inc. S-1/A                  2:161K                                   M2 Compliance LLC/FA
 4/05/21  Kraig Biocraft Laboratories, Inc. S-1                   63:6M                                     M2 Compliance LLC/FA
 2/18/21  Kraig Biocraft Laboratories, Inc. S-1/A                 78:9.1M                                   M2 Compliance LLC/FA
 2/08/21  Kraig Biocraft Laboratories, Inc. S-1/A                 78:9.1M                                   M2 Compliance LLC/FA
 8/24/20  Kraig Biocraft Laboratories, Inc. S-1/A                 68:7.8M                                   M2 Compliance LLC/FA
Top
Filing Submission 0001493152-20-010402   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 11:15:36.2am ET